Actress and Osteoporosis Advocate Sally Field Salutes Women's Health Innovators and Encourages American Women to 'Rally With Sally' for Bone Health

Aug 02, 2006, 01:00 ET from Roche from ,GSK

    NEW YORK, Aug. 2 /PRNewswire/ -- In a ceremony today, at the first
 annual Ladies' Home Journal Health Breakthrough Awards, Sally Field,
 Oscar-winning actress and advocate for osteoporosis education, honored
 medical professionals whose breakthroughs have benefited women's health.
     (Logo: )
     "For me personally and for so many other women, the dedicated efforts
 of these medical professionals have given us chances that our mothers and
 grandmothers never had in facing diseases head on, and thriving," said
 Field, who was diagnosed with osteoporosis in 2005. At that time, Field
 began an active osteoporosis management program and treats her condition
 with once-monthly Boniva(R) (ibandronate sodium), a prescription medicine
 for postmenopausal osteoporosis.
     A baby boomer who turns 60 in November, Field continues to lead an
 active life -- including filming her upcoming fall show "Brothers &
 Sisters," which will air on ABC, and rallying women nationwide to work
 toward better bone health at and 877-BoneHealth.
     "Already 50,000 Web visitors have joined me online to learn how to
 treat their bones right. It's important to keep the momentum, so I'm
 encouraging women to tell their friends and family members about Helping more women learn about osteoporosis and how to
 maintain good bone health is what it's all about," she said. The Rally With
 Sally For Bone Health(SM) campaign is sponsored by Roche and
     Field presented honors to the medical professionals at the Ladies' Home
 Journal Health Breakthrough Awards in Manhattan. Created to recognize
 medical professionals whose work has improved women's lives, the awards
 were given to:
     -- Frank Speizer, M.D., and Walter Willett, M.D., both of Harvard Medical
        School, for their work with The Nurses Health Study, which has examined
        chronic diseases in women over the past 30 years, including
     -- Deborah K. Armstrong, M.D., of Johns Hopkins School of Medicine,
        Baltimore, for her research into ovarian cancer
     -- Susan Cu-Uvin, M.D., of Brown Medical School, for setting up the
        nation's first HIV/AIDS menopause clinic
     -- Mary Ann Keenan, M.D., of University of Pennsylvania, for pioneering
        surgical techniques that relieve musculo/skeletal deformities brought
        on by stroke
     -- Etta Pisano, M.D., of University of North Carolina, for research into
        digital mammograms, and
     -- Marianne Legato, M.D., of Columbia University, for helping to establish
        and promote gender-specific medicine.
     The Ladies' Home Journal Health Breakthrough Awards are sponsored by
     About Boniva(R) (ibandronate sodium)
     Boniva Tablets are contraindicated in patients unable to stand or sit
 upright for at least 60 minutes, with uncorrected hypocalcemia, or with
 known hypersensitivity to any component of Boniva. Boniva, like other
 bisphosphonates administered orally, may cause upper gastrointestinal
 disorders such as dysphagia, esophagitis, and esophageal or gastric ulcer.
 Boniva is not recommended in patients with severe renal impairment.
 Adequate intake of calcium and vitamin D is important in all patients.
     Patients have reported severe bone, joint and/or muscle pain after
 taking bisphosphonate therapy for osteoporosis. Additionally, osteonecrosis
 of the jaw has been reported in patients treated with bisphosphonates; most
 cases have been in cancer patients undergoing dental procedures.
     The most commonly reported adverse events with once-monthly Boniva
 regardless of causality were abdominal pain (Boniva 150 mg 7.8 percent vs.
 Boniva 2.5 mg 5.3 percent), hypertension (6.3 percent vs. 7.3 percent),
 dyspepsia (5.6 percent vs. 7.1 percent), arthralgia (5.6 percent vs. 3.5
 percent), nausea (5.1 percent vs. 4.8 percent) and diarrhea (5.1 percent
 vs. 4.1 percent). For complete prescribing information for Boniva, see
 contact information at the end of the news release or go to
     About Roche and GlaxoSmithKline
     Hoffmann-La Roche, Inc. (Roche) and GlaxoSmithKline (GSK) have a
 worldwide collaboration (excluding Japan) to promote Boniva for the
 treatment and prevention of postmenopausal osteoporosis.
     Roche is one of the world's leading innovation-driven healthcare
 groups. Its core businesses are pharmaceuticals and diagnostics. Roche has
 alliances and research and development agreements with numerous partners,
 including majority ownership interests in Genentech and Chugai. For further
 information, visit
     GSK, one of the world's leading research-based pharmaceutical and
 healthcare companies, is committed to improving the quality of human life
 by enabling people to do more, feel better and live longer. For company
 information, visit GSK on the World Wide Web at
     Boniva is a registered trademark of Roche Therapeutics, Inc. Rally With
 Sally For Bone Health is a service mark of Roche Therapeutics, Inc.
     For more information or full prescribing information, contact:
     Maureen Byrne        (973) 562-2203
     Bradd Pavur          (919) 483-2839
     Barbara Goldberg
     212-229-8419 (o)
     917-841-5046 (cell)